AR008094A1 - Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica. - Google Patents

Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica.

Info

Publication number
AR008094A1
AR008094A1 ARP970103413A ARP970103413A AR008094A1 AR 008094 A1 AR008094 A1 AR 008094A1 AR P970103413 A ARP970103413 A AR P970103413A AR P970103413 A ARP970103413 A AR P970103413A AR 008094 A1 AR008094 A1 AR 008094A1
Authority
AR
Argentina
Prior art keywords
parathyroid hormone
synthesis
preparation
pharmaceutical composition
synthetic polypeptide
Prior art date
Application number
ARP970103413A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR008094A1 publication Critical patent/AR008094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Un proceso para la síntesis de un polipéptido sintético análogo a la hormona paratiroidea (PTH) o al péptido relacionado con la hormonaparatiroidea (PTHrP), o una sal del mismo, en el que los residuos aminoácidos (22-31) seleccionados deen tre (SEQ ID Nos.; 85, 86, 26, 27, 28, 29 y 30)forman una hélice alfa anfipática, que incluye: (a) la síntesis independiente de fragmentos peptídicos precursores del polipéptido, mediante técnicas ensolución o en fase sólida; (b) la condensaciónde dichos fragmentos unos con otros para formar el producto polipeptídico deseado; y (c) la eliminaciónde los grupos protectores de aminoácidos, y proceso para la preparación de una composición farmacéutica.
ARP970103413A 1996-07-30 1997-07-28 Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica. AR008094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2332296P 1996-07-30 1996-07-30

Publications (1)

Publication Number Publication Date
AR008094A1 true AR008094A1 (es) 1999-12-09

Family

ID=21814418

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970103413A AR008094A1 (es) 1996-07-30 1997-07-28 Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica.
ARP990100625A AR016981A2 (es) 1996-07-30 1999-02-16 Polipeptidos sinteticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990100625A AR016981A2 (es) 1996-07-30 1999-02-16 Polipeptidos sinteticos

Country Status (30)

Country Link
US (1) US6849710B1 (es)
EP (1) EP0822200B1 (es)
JP (1) JP4229992B2 (es)
KR (1) KR100518982B1 (es)
CN (1) CN1293096C (es)
AR (2) AR008094A1 (es)
AT (1) ATE277080T1 (es)
AU (1) AU731160B2 (es)
BR (1) BR9704138A (es)
CA (1) CA2206008C (es)
CO (1) CO4650046A1 (es)
CZ (1) CZ239697A3 (es)
DE (1) DE69730787T2 (es)
DK (1) DK0822200T3 (es)
ES (1) ES2227639T3 (es)
HR (1) HRP970416A2 (es)
HU (1) HUP9701277A3 (es)
IL (1) IL121391A0 (es)
MA (1) MA24353A1 (es)
MX (1) MX9705719A (es)
NO (1) NO973482L (es)
NZ (1) NZ328411A (es)
PE (1) PE91998A1 (es)
PL (1) PL321391A1 (es)
SG (1) SG67408A1 (es)
TR (1) TR199700714A2 (es)
TW (1) TW505654B (es)
UY (1) UY24651A1 (es)
YU (1) YU32197A (es)
ZA (1) ZA976555B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006728A (es) * 2002-01-10 2005-08-19 Osteotrophin Llc Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos.
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20090093016A1 (en) * 2006-01-17 2009-04-09 N.V. Organon Selective Enzymatic Hydrolysis of C-Terminal Tert-Butyl Esters of Peptides
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
SI2957278T1 (sl) 2006-10-03 2017-09-29 Radius Health, Inc. Stabilni sestavek, ki obsega PTHrP, in njegova uporaba
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN102993293B (zh) * 2012-12-05 2014-05-07 深圳翰宇药业股份有限公司 一种特立帕肽醋酸盐的纯化方法
WO2014147129A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
CN104530198B (zh) * 2014-12-09 2017-09-15 兰州大学 一种片段缩合制备醋酸去氨加压素的方法
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
CN111057139B (zh) * 2018-10-17 2023-12-22 南京华威医药科技集团有限公司 一种制备特立帕肽的新工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
AU667662B2 (en) * 1990-07-13 1996-04-04 Regents Of The University Of California, The Parathyroid hormone analogues modified at positions 3, 6 or 9
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CN1070500C (zh) * 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN

Also Published As

Publication number Publication date
HRP970416A2 (en) 1998-08-31
HU9701277D0 (en) 1997-09-29
NO973482D0 (no) 1997-07-29
DK0822200T3 (da) 2005-01-31
UY24651A1 (es) 2000-12-29
MA24353A1 (fr) 1998-07-01
PL321391A1 (en) 1998-02-02
ZA976555B (en) 1998-01-30
CZ239697A3 (cs) 1998-04-15
TW505654B (en) 2002-10-11
CA2206008A1 (en) 1998-01-30
KR980009282A (ko) 1998-04-30
JP4229992B2 (ja) 2009-02-25
DE69730787T2 (de) 2005-10-13
BR9704138A (pt) 1998-12-29
TR199700714A2 (xx) 1998-02-21
MX9705719A (es) 1998-02-28
HUP9701277A2 (hu) 1998-11-30
CO4650046A1 (es) 1998-09-03
HUP9701277A3 (en) 2001-02-28
PE91998A1 (es) 1998-12-31
CN1293096C (zh) 2007-01-03
NZ328411A (en) 1998-12-23
EP0822200A1 (en) 1998-02-04
AR016981A2 (es) 2001-08-01
JPH1077295A (ja) 1998-03-24
ES2227639T3 (es) 2005-04-01
CN1174845A (zh) 1998-03-04
ATE277080T1 (de) 2004-10-15
EP0822200B1 (en) 2004-09-22
KR100518982B1 (ko) 2006-05-29
US6849710B1 (en) 2005-02-01
IL121391A0 (en) 1998-01-04
NO973482L (no) 1998-02-02
SG67408A1 (en) 1999-09-21
CA2206008C (en) 2008-09-23
AU731160B2 (en) 2001-03-22
YU32197A (sh) 1999-07-28
AU3236297A (en) 1998-02-05
DE69730787D1 (de) 2004-10-28

Similar Documents

Publication Publication Date Title
AR008094A1 (es) Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica.
FI89060C (fi) Foerfarnde foer framstaellning av terapeutiskt anvaendbara peptidderivat
FI950169A0 (fi) PTH:n ja PTHRP:n analogit, niiden synteesi ja käyttö osteoporoosin hoitoon
AU1918300A (en) Amino-terminal modified parathyroid hormone (pth) analogs
DK262683D0 (da) Dynorphinamidanaloger
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
KR930000536A (ko) A-c-b 프로인슐린, 그의 제조방법, 그의 용도 및 인슐린 생산을 위한 중간체
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
EP0346500A4 (en) Elastase inhibiting polypeptides and process for their preparation by genetic recombination
Tregear et al. Synthetic analogues of residues 1-34 of human parathyroid hormone: influence of residue number 1 on biological potency in vitro
JPH0222292A (ja) 高カルシウム体液性因子拮抗薬
Chartier et al. Primary structure of the chromosomal proteins MC1a, MC1b, and MC1c from the archaebacterium Methanothrix soehngenii
Deschodt-Lanckman et al. Cholecystokinin octa-and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
Rohde et al. Structure of antigenic determinants in the N-terminal region of dermatosparactic sheep procollagen type I
JPS56108750A (en) Polypeptide and its preparation
Hlaváček et al. Utilization of some non coded amino acids as isosters of peptide building blocks
AR122306A1 (es) Variantes del cnp y sus conjugados
CO5090903A1 (es) Nuevos peptidos para ser usados en una terapia de tolerancia inducida para impedir las alteraciones autoinmunes, en particular, artritis reumatoidea
TH33861A (th) วิธีการสังเคราะห์ฮอร์โมนพาราไธรอยด์ และเปปไตต์ที่เกี่ยวกับฮอร์โมนพาราไธรอยด์
Jones Polypeptides. Part XIII. Peptides related to the C-terminal tetrapeptide sequence of the gastrins by complementary reading of the genetic message
KR930703345A (ko) 펩타이드의 액상 합성법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal